secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001104659-22-060822
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q1 2022 net loss $5.4M, cash $18.4M; progresses NurOwn ALS program
-----------------------------------------------------------------------------

- Net loss $5.4M ($0.15/sh) improved from $6.7M ($0.19/sh) in Q1 2021.
- Cash $18.4M at Mar 31, down from $22.1M at Dec 31, 2021.
- R&D spend cut to $2.6M from $4.3M; G&A rose to $2.9M from $2.6M.
- Presented Phase 3 NurOwn biomarker data at AAN 2022; genetic analysis at MDA conference.
- Appointed Netta Blundheim-Shraga as VP R&D and Antal Pearl-Lendener as Chief Legal Counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/0001104659-22-060822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465922060822/tm2215644d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-060822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer